questionsmedicales.fr
Actions chimiques et utilisations
Actions toxiques
Noxas
Antimétabolites
Antimétabolites : Questions médicales fréquentes
Termes MeSH sélectionnés :
Speech-Language Pathology
Diagnostic
5
Toxicité médicamenteuse
Antimétabolites
Biopsie
Imagerie médicale
Syndrome de surdosage
Antimétabolites
Effets secondaires
Antimétabolites
Marqueurs tumoraux
Antimétabolites
Symptômes
5
Immunosuppression
Infections
Réaction allergique
Antimétabolites
Douleurs abdominales
Antimétabolites
Prévention
5
Surveillance médicale
Antimétabolites
Tests de fonction hépatique
Antimétabolites
Antiémétiques
Antimétabolites
Protocoles d'administration
Antimétabolites
Éducation des patients
Antimétabolites
Traitements
5
Analogues des purines
Analogues des pyrimidines
Administration intraveineuse
Antimétabolites
Chimiothérapie combinée
Inhibiteurs de la tyrosine kinase
Durée du traitement
Antimétabolites
Traitement adjuvant
Antimétabolites
Complications
5
Cancers secondaires
Antimétabolites
Infections
Immunosuppression
Hépatotoxicité
Antimétabolites
Surveillance médicale
Antimétabolites
Facteurs de risque
5
Âge avancé
Interactions médicamenteuses
Antécédents médicaux
Antimétabolites
Mode de vie
Antimétabolites
Interactions médicamenteuses
Antimétabolites
Facteurs génétiques
Antimétabolites
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antimétabolites : Questions médicales les plus fréquentes",
"headline": "Antimétabolites : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antimétabolites : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-11",
"dateModified": "2025-04-06",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antimétabolites"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Noxas",
"url": "https://questionsmedicales.fr/mesh/D009676",
"about": {
"@type": "MedicalCondition",
"name": "Noxas",
"code": {
"@type": "MedicalCode",
"code": "D009676",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.888.569"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Antimétabolites antinéoplasiques",
"alternateName": "Antimetabolites, Antineoplastic",
"url": "https://questionsmedicales.fr/mesh/D000964",
"about": {
"@type": "MedicalCondition",
"name": "Antimétabolites antinéoplasiques",
"code": {
"@type": "MedicalCode",
"code": "D000964",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.888.569.042.030"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Antimétabolites",
"alternateName": "Antimetabolites",
"code": {
"@type": "MedicalCode",
"code": "D000963",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "John A Gonzales",
"url": "https://questionsmedicales.fr/author/John%20A%20Gonzales",
"affiliation": {
"@type": "Organization",
"name": "F.I. Proctor Foundation, University of California, San Francisco, California; Department of Ophthalmology, University of California, San Francisco, California."
}
},
{
"@type": "Person",
"name": "Radhika Thundikandy",
"url": "https://questionsmedicales.fr/author/Radhika%20Thundikandy",
"affiliation": {
"@type": "Organization",
"name": "Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India."
}
},
{
"@type": "Person",
"name": "Anuradha Kanakath",
"url": "https://questionsmedicales.fr/author/Anuradha%20Kanakath",
"affiliation": {
"@type": "Organization",
"name": "Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Coimbatore, India."
}
},
{
"@type": "Person",
"name": "Hassan A Al-Dhibi",
"url": "https://questionsmedicales.fr/author/Hassan%20A%20Al-Dhibi",
"affiliation": {
"@type": "Organization",
"name": "Division of Vitreoretinal Surgery and Uveitis, King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia."
}
},
{
"@type": "Person",
"name": "Nisha R Acharya",
"url": "https://questionsmedicales.fr/author/Nisha%20R%20Acharya",
"affiliation": {
"@type": "Organization",
"name": "F.I. Proctor Foundation, University of California, San Francisco, California; Department of Ophthalmology, University of California, San Francisco, California; Department of Epidemiology and Biostatistics, University of California, San Francisco, California. Electronic address: nisha.acharya@ucsf.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Practice-Based Coaching for Speech-Language Pathologists Supporting Paraeducators and Speech-Language Pathology Assistants.",
"datePublished": "2022-12-13",
"url": "https://questionsmedicales.fr/article/36512758",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1044/2022_LSHSS-22-00068"
}
},
{
"@type": "ScholarlyArticle",
"name": "Predictors of Speech Language Pathology Referral After Pediatric Concussion Using a Speech Language Checklist.",
"datePublished": "2023-05-18",
"url": "https://questionsmedicales.fr/article/37205745",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/PHM.0000000000002293"
}
},
{
"@type": "ScholarlyArticle",
"name": "Tutorial: Data Collection and Documentation Strategies for Speech-Language Pathologist/Speech-Language Pathology Assistant Teams.",
"datePublished": "2022-07-12",
"url": "https://questionsmedicales.fr/article/35858269",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1044/2022_LSHSS-21-00151"
}
},
{
"@type": "ScholarlyArticle",
"name": "Treatment of Speech Sound Errors in Cleft Palate: A Tutorial for Speech-Language Pathology Assistants.",
"datePublished": "2023-01-04",
"url": "https://questionsmedicales.fr/article/36599098",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1044/2022_LSHSS-22-00071"
}
},
{
"@type": "ScholarlyArticle",
"name": "What Is Clinical Evidence in Speech-Language Pathology? A Scoping Review.",
"datePublished": "2022-11-08",
"url": "https://questionsmedicales.fr/article/36346976",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1044/2022_AJSLP-22-00203"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions toxiques",
"item": "https://questionsmedicales.fr/mesh/D004786"
},
{
"@type": "ListItem",
"position": 4,
"name": "Noxas",
"item": "https://questionsmedicales.fr/mesh/D009676"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antimétabolites",
"item": "https://questionsmedicales.fr/mesh/D000963"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antimétabolites - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antimétabolites",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antimétabolites",
"description": "Comment diagnostique-t-on une toxicité aux antimétabolites ?\nQuels tests sont utilisés pour évaluer l'efficacité des antimétabolites ?\nQuels signes cliniques indiquent une surdose d'antimétabolites ?\nComment évaluer les effets secondaires des antimétabolites ?\nQuels marqueurs tumoraux sont surveillés lors d'un traitement ?",
"url": "https://questionsmedicales.fr/mesh/D000963?mesh_terms=Speech-Language+Pathology#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antimétabolites",
"description": "Quels sont les symptômes courants des effets secondaires ?\nComment les antimétabolites affectent-ils le système immunitaire ?\nQuels symptômes indiquent une réaction allergique ?\nLes antimétabolites causent-ils des douleurs ?\nQuels symptômes peuvent indiquer une anémie due aux antimétabolites ?",
"url": "https://questionsmedicales.fr/mesh/D000963?mesh_terms=Speech-Language+Pathology#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antimétabolites",
"description": "Comment prévenir les effets secondaires des antimétabolites ?\nY a-t-il des mesures préventives avant le traitement ?\nComment gérer les nausées induites par les antimétabolites ?\nQuelles précautions prendre lors de l'administration ?\nLes patients doivent-ils être informés des effets secondaires ?",
"url": "https://questionsmedicales.fr/mesh/D000963?mesh_terms=Speech-Language+Pathology#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antimétabolites",
"description": "Quels types d'antimétabolites existent ?\nComment sont administrés les antimétabolites ?\nQuels sont les traitements combinés avec les antimétabolites ?\nQuelle est la durée typique d'un traitement par antimétabolites ?\nLes antimétabolites sont-ils utilisés en traitement adjuvant ?",
"url": "https://questionsmedicales.fr/mesh/D000963?mesh_terms=Speech-Language+Pathology#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antimétabolites",
"description": "Quelles sont les complications possibles des antimétabolites ?\nLes antimétabolites peuvent-ils causer des cancers secondaires ?\nComment gérer une infection due à l'immunosuppression ?\nQuels sont les risques de toxicité hépatique ?\nComment prévenir les complications liées aux antimétabolites ?",
"url": "https://questionsmedicales.fr/mesh/D000963?mesh_terms=Speech-Language+Pathology#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antimétabolites",
"description": "Quels facteurs augmentent le risque d'effets secondaires ?\nLes antécédents médicaux influencent-ils le traitement ?\nLe mode de vie affecte-t-il l'efficacité des antimétabolites ?\nLes interactions médicamenteuses sont-elles un risque ?\nLes facteurs génétiques influencent-ils la réponse au traitement ?",
"url": "https://questionsmedicales.fr/mesh/D000963?mesh_terms=Speech-Language+Pathology#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on une toxicité aux antimétabolites ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La toxicité est diagnostiquée par des tests sanguins et l'évaluation des symptômes cliniques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité des antimétabolites ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des biopsies tumorales et des imageries médicales sont utilisées pour évaluer la réponse au traitement."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent une surdose d'antimétabolites ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des nausées, des vomissements et une fatigue extrême peuvent indiquer une surdose."
}
},
{
"@type": "Question",
"name": "Comment évaluer les effets secondaires des antimétabolites ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par l'observation clinique et des tests de laboratoire réguliers."
}
},
{
"@type": "Question",
"name": "Quels marqueurs tumoraux sont surveillés lors d'un traitement ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs comme le CA 19-9 ou le PSA peuvent être surveillés selon le type de cancer."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des effets secondaires ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent nausées, fatigue, perte d'appétit et troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Comment les antimétabolites affectent-ils le système immunitaire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent provoquer une immunosuppression, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une réaction allergique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, démangeaisons et gonflements peuvent signaler une allergie."
}
},
{
"@type": "Question",
"name": "Les antimétabolites causent-ils des douleurs ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs abdominales et musculaires peuvent survenir comme effets secondaires."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une anémie due aux antimétabolites ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, pâleur et essoufflement peuvent indiquer une anémie causée par le traitement."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets secondaires des antimétabolites ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance régulière et des ajustements de dose peuvent aider à prévenir les effets secondaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives avant le traitement ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests de fonction hépatique et rénale sont souvent effectués avant le traitement."
}
},
{
"@type": "Question",
"name": "Comment gérer les nausées induites par les antimétabolites ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antiémétiques peuvent être prescrits pour gérer les nausées et vomissements."
}
},
{
"@type": "Question",
"name": "Quelles précautions prendre lors de l'administration ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est essentiel de suivre les protocoles d'administration pour éviter les erreurs de dosage."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils être informés des effets secondaires ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation des patients sur les effets secondaires est cruciale pour une bonne observance."
}
},
{
"@type": "Question",
"name": "Quels types d'antimétabolites existent ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux types incluent les analogues des purines et des pyrimidines."
}
},
{
"@type": "Question",
"name": "Comment sont administrés les antimétabolites ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être administrés par voie orale ou intraveineuse, selon le médicament."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements combinés avec les antimétabolites ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont souvent combinés avec des agents alkylants ou des inhibiteurs de la tyrosine kinase."
}
},
{
"@type": "Question",
"name": "Quelle est la durée typique d'un traitement par antimétabolites ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée varie, mais elle est généralement de plusieurs semaines à plusieurs mois."
}
},
{
"@type": "Question",
"name": "Les antimétabolites sont-ils utilisés en traitement adjuvant ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont souvent utilisés en traitement adjuvant après chirurgie pour réduire les récidives."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des antimétabolites ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'immunosuppression, l'anémie et des troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Les antimétabolites peuvent-ils causer des cancers secondaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains antimétabolites sont associés à un risque accru de cancers secondaires."
}
},
{
"@type": "Question",
"name": "Comment gérer une infection due à l'immunosuppression ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement antibiotique précoce et une surveillance étroite sont essentiels."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de toxicité hépatique ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antimétabolites peuvent provoquer une hépatotoxicité, nécessitant un suivi régulier."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées aux antimétabolites ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance régulière et des ajustements de traitement peuvent aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'effets secondaires ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, les comorbidités et les interactions médicamenteuses augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le traitement ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies hépatiques ou rénales peuvent influencer le choix du traitement."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il l'efficacité des antimétabolites ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation déséquilibrée et le tabagisme peuvent réduire l'efficacité du traitement."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses sont-elles un risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines interactions peuvent augmenter la toxicité ou diminuer l'efficacité des antimétabolites."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques influencent-ils la réponse au traitement ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des variations génétiques peuvent affecter la métabolisation des antimétabolites."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 06/04/2025
Contenu vérifié selon les dernières recommandations médicales
6 publications dans cette catégorie
Affiliations :
F.I. Proctor Foundation, University of California, San Francisco, California; Department of Ophthalmology, University of California, San Francisco, California.
6 publications dans cette catégorie
Affiliations :
Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India.
6 publications dans cette catégorie
Affiliations :
Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Coimbatore, India.
6 publications dans cette catégorie
Affiliations :
Division of Vitreoretinal Surgery and Uveitis, King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia.
6 publications dans cette catégorie
Affiliations :
F.I. Proctor Foundation, University of California, San Francisco, California; Department of Ophthalmology, University of California, San Francisco, California; Department of Epidemiology and Biostatistics, University of California, San Francisco, California. Electronic address: nisha.acharya@ucsf.edu.
5 publications dans cette catégorie
Affiliations :
Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
Publications dans "Antimétabolites" :
5 publications dans cette catégorie
Affiliations :
Casey Eye Institute, Oregon Health and Science University, Portland, Oregon.
Publications dans "Antimétabolites" :
5 publications dans cette catégorie
Affiliations :
F.I. Proctor Foundation, University of California, San Francisco, California; Department of Ophthalmology, University of California, San Francisco, California.
Publications dans "Antimétabolites" :
4 publications dans cette catégorie
Publications dans "Antimétabolites" :
4 publications dans cette catégorie
Affiliations :
Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India.
Publications dans "Antimétabolites" :
3 publications dans cette catégorie
Affiliations :
Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India.
Publications dans "Antimétabolites" :
3 publications dans cette catégorie
Affiliations :
F.I. Proctor Foundation, University of California, San Francisco, California; Department of Ophthalmology, University of California, San Francisco, California; Department of Epidemiology and Biostatistics, University of California, San Francisco, California.
Publications dans "Antimétabolites" :
3 publications dans cette catégorie
Affiliations :
Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Uvea Services, Pondicherry, India.
Publications dans "Antimétabolites" :
3 publications dans cette catégorie
Affiliations :
Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Uvea Services, Madurai, India.
Publications dans "Antimétabolites" :
2 publications dans cette catégorie
Affiliations :
c Rexahn Pharmaceuticals, Inc , Rockville , MD , USA.
Publications dans "Antimétabolites" :
2 publications dans cette catégorie
Affiliations :
c Rexahn Pharmaceuticals, Inc , Rockville , MD , USA.
Publications dans "Antimétabolites" :
2 publications dans cette catégorie
Affiliations :
c Rexahn Pharmaceuticals, Inc , Rockville , MD , USA.
Publications dans "Antimétabolites" :
2 publications dans cette catégorie
Affiliations :
Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India.
Publications dans "Antimétabolites" :
2 publications dans cette catégorie
Affiliations :
Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Pondicherry, India.
Publications dans "Antimétabolites" :
2 publications dans cette catégorie
Affiliations :
F.I. Proctor Foundation, University of California, San Francisco, California.
Publications dans "Antimétabolites" :
This tutorial is designed for speech-language pathologists who supervise speech-language pathology assistants (SLP-As) and/ or paraeducators. SLP-As and paraeducators often support young children with...
In this tutorial, we will share the components of PBC including implementation materials that can be immediately utilized by SLPs. We will also share methods for embedding effective vocabulary instruc...
Speech language pathologists have the training to treat pediatric concussion issues in communication; however, they have traditionally not been included in initial concussion treatment. Despite physic...
This tutorial outlines an approach for best practices for speech-language pathology assistants (SLPAs) to collect data and document services. The tutorial outlines methods for developing accurate and ...
Developing competence with a wide variety of data collection methods, data types, and documentation tools will assist SLPAs to accurately communicate the results of the services they provide, therefor...
https://doi.org/10.23641/asha.20277726....
Cleft palate is one of the most common birth defects in the United States. Most of these children receive speech therapy by preschool and school-based clinicians. The purpose of this article is to pro...
It has been reported that 68% of preschoolers with repaired cleft palate received speech therapy. Preschool and school-based speech-language pathologists (SLPs) have reported a strong desire for pract...
SLPAs will learn elicitation techniques for compensatory articulations and implement evidence-based treatment approaches to improve the speech accuracy of children with cleft palate....
It is important for all school-based clinicians to be familiar with speech therapy for individuals with cleft palate....
Two disparate models drive American speech-language pathologists' views of evidence-based practice (EBP): the American Speech-Language-Hearing Association's (2004a, 2004b) and Dollaghan's (2007). Thes...
We conducted a scoping review to identify terms ascribed to clinical evidence and their descriptions. We searched the peer-reviewed, accessible, speech-language pathology intervention literature from ...
Seventy-eight articles included a description of clinical evidence. Across publications, a single term was used to describe disparate concepts, and the same concept was given different terms, yet the ...
These results outline a shared language for SLPs to discuss their clinical evidence with researchers, families, allied professionals, and each other. Clarification of the terminology, associated defin...
https://doi.org/10.23641/asha.21498546....
The study aimed to evaluate patient satisfaction with speech-language therapy televisits and to identify factors influencing the level of satisfaction....
Participants were recruited from an academic tertiary voice and swallowing center who had completed ≥1 telehealth session of speech-language therapy with a speech-language pathologist between March, 2...
65/239 patients completed the SAPS survey, representing a response rate of 27%. The average age of study participants was 54.92 ± 16.45 years, with 49.2% identifying as female, 33.9% as male, and 16.9...
Clinicians are able to achieve high patient satisfaction with speech-language therapy when delivered by telehealth. Patient satisfaction remained high across diverse patient populations and range of c...
Clinicians are able to achieve high patient satisfaction with speech-language therapy when delivered via telehealth. Satisfaction remained high regardless of gender identity, type of therapy received,...
4 Laryngoscope, 133:895-900, 2023....
Ideologies are like rocks onto which individuals and institutions anchor their thoughts about what it means to be an "ideal language user" and what "standardized languaging" is. These deeply ingrained...
Ideologies uphold idealized versions of "normality" and constructions of "deviance." Left unexamined, these beliefs remain encoded in traditionally considered scientific categories, policies, approach...
To validate the content of the Speech-Language Pathology Concordance Test called FonoTCS....
This is a content validation study of the instrument. Five speech-language pathologists, all with doctoral degrees and teaching experience, averaging 24.8 years of professional practice, participated ...
Thirteen evaluators, all female, with an average age of 39.07 years, including eight with master's degrees and five with doctoral degrees, and an average clinical practice experience of 15.38 years, p...
FonoTCS is a valid instrument from a content perspective....
Graduate programs often use practicum experience with clients from nonmajority cultures to improve students' cultural responsiveness. Yet, it is not clear whether simply working with a client from a n...
Twenty first-year speech-language pathology graduate students (10 Spanish-English bilinguals, 10 monolingual English speakers) were split into three groups: monolingual experimental (...
Experience working with bilingual clients did not have a substantial effect on students' confidence in their cultural competence. No substantial change was found in cultural responsiveness on the thin...
Simply working with clients from nonmajority cultures does not create a scenario where cultural responsiveness is likely to improve. Additional targeted, purposeful training in cultural responsiveness...
To compare the results of fluency and self-perception of the impact of stuttering on the lives of adults who stutter, before and after undergoing intensive speech-language pathology therapy....
This is a descriptive and longitudinal study with data collection before and after intensive therapy in four patients who stutter. The intensive care program consisted of thirty one-hour sessions held...
There was a reduction of the percentage of stuttering disfluencies, increasing the flow of words per minute of the participants. The descriptive analysis of the OASES-A showed a decrease in the degree...
There was an improvement in all variables analyzed after intensive care, including an improvement in speech fluency and a reduction in the impact of stuttering on the participants' lives, which sugges...